Queen Mary University of London spin-out Activiomics enters into research programme with Kyowa Hakko Kirin.
Life sciences firm Activiomics has built on its contract research agreement with Japan-based pharmaceutical firm Kyowa Hakko Kirin (KHK) by entering into a new research programme.
The London-based Queen Mary University of London spin-out will apply its cell signalling TIQUAS platform to lead compounds supplied by KHK.
Activiomics has received $805k in venture funding. The financing came from a 2011 venture round, backed solely by commercialisation firm the IP Group.
Hiroshi Okazaki, managing officer at Kyowa Hakko Kirin, said: “We…
